IDH1 and glioblastoma: Further studies on the interplay between glioma cells with the IME, especially in “Glioblastoma, IDH wildtype”, are urgent to be carried out to identify more molecular biomarkers, which are promising to provide guidance for targeted therapy and immunotherapy.